Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd executive Orit Pinchuk, VP Regulatory Affairs, filed an initial Form 3 reporting her equity position in the company. She directly holds 12,133 Ordinary Shares.
She also holds several option grants to purchase Ordinary Shares, including one grant exercisable for 15,000 shares at $6.15 per share, expiring on August 28, 2028, and additional grants each covering 15,000 shares at $7.55 per share with an expiration date of October 22, 2035 and different future exercise dates. The options are exercisable using a net-exercise method, and the U.S. dollar exercise prices are convenience translations from NIS based on the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd executive Beladev Shavit, VP Plasma Operations, has filed an initial ownership report. Shavit directly holds 3,418 Ordinary Shares and several option grants to purchase additional Ordinary Shares at exercise prices of $6.15 and $7.55, with expirations between 2028 and 2035. These options are exercisable using a net-exercise method, and the U.S. dollar exercise prices reflect translation from NIS based on the Bank of Israel’s representative exchange rate as of March 13, 2026.
Kamada Ltd VP of Marketing & Sales Hanni Neheman has filed an initial ownership report showing ordinary shares and stock options in the company. The filing lists direct ownership of 3,417 ordinary shares and several option grants over ordinary shares with exercise prices of $6.15 and $7.55 per share, expiring between 2028 and 2035. The options are exercisable using a net-exercise method, and the exercise prices shown in U.S. dollars reflect a translation from New Israeli Shekels based on the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd director David Tsur has filed an initial ownership report showing direct holdings of 607,929 Ordinary Shares of the company.
He also holds several grants of options to purchase Ordinary Shares, each covering either 6,625 or 7,500 underlying shares at exercise prices of $7.5200 and $6.1500, with expiration dates ranging from September 25, 2026 to June 22, 2029. According to the footnotes, these options are exercisable using a net-exercise method, and the exercise prices shown in U.S. dollars reflect a convenience translation from NIS based on the Bank of Israel representative exchange rate as of March 13, 2026.
Kamada Ltd executive Nir Eran, Vice President of Operations, has reported his initial holdings as an insider. He directly holds 10,398 Ordinary Shares. He also holds options to purchase Ordinary Shares, including a grant for 22,500 shares at an exercise price of 6.1500 expiring on August 28, 2028, and additional grants for 22,500 underlying shares each at an exercise price of 7.5500 expiring on October 22, 2035, with exercise eligibility beginning on various dates between October 22, 2026 and October 22, 2029. The options are exercisable using a net-exercise method, and the exercise prices shown in U.S. dollars are convenience translations from NIS using the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd VP Quality Yael Brenner has filed an initial insider report listing her equity interests in the company. The filing shows direct ownership of 6,266 Ordinary Shares, along with several options to purchase Ordinary Shares, each for 15,000 underlying shares at exercise prices of $6.15 and $7.55 per share with expirations in 2028 and 2035. The options are exercisable using a net-exercise method, meaning only the in-the-money value is settled in shares.
Kamada Ltd executive Reshef Liron, VP Human Resources, filed an initial ownership report showing holdings of stock options on the company’s ordinary shares. The options are exercisable using a net-exercise method and their exercise prices in U.S. dollars reflect a translation from NIS as of March 13, 2026.
The holdings include option tranches for 10,000 ordinary shares at an exercise price of $5.33 per share expiring in 2029, and tranches for 15,000 ordinary shares at an exercise price of $7.55 per share expiring in 2035, all held directly.
Kamada Ltd director Karnit Goldwasser filed an initial Form 3 reporting holdings of stock options on Ordinary Shares. The filing lists several option grants with exercise prices of 7.5200 and 6.1500 per share, expiring between September 25, 2026 and June 22, 2029. Each grant covers either 6,625 or 7,500 underlying Ordinary Shares and is held directly. The options are exercisable using a net-exercise method, and the exercise prices in U.S. dollars reflect a convenience translation from NIS based on the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd. Chief Financial Officer Chaime Orlev has filed an initial Form 3 reporting his equity holdings in the company. He directly owns 11,633 Ordinary Shares and holds several grants of options to purchase Ordinary Shares, each covering 22,500 underlying shares at exercise prices of 6.18, 6.15 and 7.55 per share, with expirations between 2028-08-28 and 2035-10-22. The options are exercisable using a net-exercise method, and the exercise prices in U.S. dollars are convenience translations from NIS based on the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd director Leon Recanati filed an initial ownership report showing substantial holdings in the company. He directly owns 631,143 Ordinary Shares and indirectly holds 1,455,459 Ordinary Shares through GOV Holdings and 1,346,335 Ordinary Shares through Insight. He also holds several option grants to purchase Ordinary Shares at exercise prices of $7.52 and $6.15, with expirations in 2026 and 2029. The options are exercisable using a net-exercise method, which settles only the in-the-money value in shares rather than requiring full cash payment.